Glenmark Pharma Gets Tentative Usfda Nod For Generic Anti-Diabetes Tablets
Glenmark Pharmaceuticals On Wednesday Said It Has Received Tentative Approval From The Us Health Regulator For Its Generic Dapagliflozin And Saxagliptin Anti-Diabetes Tablets. The Approval Granted By The United States Food And Drug Administration (Usfda) To Glenmark Pharmaceuticals Inc., Usa, Is For The Strength Of 10 Mg/5 Mg Tablets, The Generic Version Of Qtern Tablets Of The Same Strength Of Astrazeneca Ab, The Company Said In A Statement.Citing Iqvia Sales Data For The 12-Month Period Ending February 2020, The Company Said Qtern Tablets, 10 Mg/5 Mg Had Achieved Annual Sales Of Approximately Usd 10.4 Million. Glenmark'S Current Portfolio Consists Of 162 Products Authorised For Distribution In The Us And 44 Abbreviated New Drug Applications Pending Approval With The Usfda, The Company Said.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
